<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055389</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00013058</org_study_id>
    <nct_id>NCT04055389</nct_id>
  </id_info>
  <brief_title>Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis</brief_title>
  <acronym>PiVoT</acronym>
  <official_title>Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Stine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prevent portal vein thrombosis (PVT) in patients with cirrhosis at risk for PVT by&#xD;
      pharmacologic prophylaxis with intravenous antithrombin (AT-III).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PVT is a common complication in patients with cirrhosis, affecting 10% to 25% of patients.&#xD;
      PVT is a potentially life-threatening occurrence, complicating transplant candidacy and&#xD;
      reducing five-year survival. In addition to the mortality risk posed by PVT, microthrombi&#xD;
      within the liver have been linked to decompensation due to the phenomenon of parenchymal&#xD;
      extinction. Because of the developing understanding of a baseline hypercoagulable state in&#xD;
      many cirrhosis patients, recent studies have demonstrated the benefit of prophylactic&#xD;
      anticoagulation with enoxaparin in patients with cirrhosis to prevent PVT. In addition to the&#xD;
      benefit in reducing PVT, prophylactic anticoagulation was also found to reduce liver&#xD;
      decompensation and improve overall survival.&#xD;
&#xD;
      Risk factors for PVT are well described. The strongest independent risk factor for PVT is&#xD;
      portal vein velocity. For each 1 cm/s decrease in portal vein velocity, PVT risk increases&#xD;
      16%. Portal vein velocity &lt;15cm/sec is the best-established cutoff for predicting the&#xD;
      development of de novo PVT over the ensuing twelve months.&#xD;
&#xD;
      In addition, patients with cirrhosis and venous thromboembolism (PVT, deep vein thrombosis,&#xD;
      pulmonary embolus) have abnormally low levels of AT-III. A recent report by the NPB-06 study&#xD;
      group suggest that administering intravenous AT-III at dosage of 1500 units/day for five&#xD;
      consecutive days in patients with cirrhosis and AT-III &lt;70% serum level is a safe and&#xD;
      effective treatment for PVT with promising short-term partial and complete resolution of PVT.&#xD;
      Despite this, the role of AT repletion in preventing PVT remains unknown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of PVT</measure>
    <time_frame>up to 72 weeks</time_frame>
    <description>incident of PVT measured by ultrasound at different time points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>AT-III treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III</intervention_name>
    <description>Patients with reversal of flow or sluggish flow in the main portal vein (&lt;15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life ~4 days) at a weight-based dosage according to the following formula:&#xD;
[Desired level of AT (100%) - Subject level of AT (%)] * subject weight (kg) 1.4&#xD;
or placebo for 24 weeks of therapy.</description>
    <arm_group_label>AT-III treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No study drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Cirrhosis documented by:&#xD;
&#xD;
          -  Liver biopsy OR&#xD;
&#xD;
          -  Clinical, imaging, and laboratory findings consistent with cirrhosis AND&#xD;
&#xD;
          -  Disease process etiologic for cirrhosis (e.g., chronic viral hepatitis, non-alcoholic&#xD;
             steatohepatitis, history of alcohol abuse, cholestatic liver disease)&#xD;
&#xD;
               -  Flow in main portal vein less than 15 cm/sec or reversal of flow as assessed by&#xD;
                  Doppler ultrasonography&#xD;
&#xD;
               -  Age greater than or equal to 18 and less than or equal to 75 years&#xD;
&#xD;
               -  AT-III &lt;70%&#xD;
&#xD;
               -  Platelet count greater than or equal to 55,000 per uL&#xD;
&#xD;
               -  Laboratories reflective of general health status (normal):&#xD;
&#xD;
          -  White blood cell count (4-10.4 K/uL)&#xD;
&#xD;
          -  Hemoglobin (11.7-15.0 g/dL) and hematocrit (35-44%)&#xD;
&#xD;
          -  Creatinine (0.60-1.00 mg/dL) â€¢ Child Pugh Turcotte (CPT) Class A cirrhosis&#xD;
&#xD;
        3.2 Exclusion Criteria&#xD;
&#xD;
          -  Allergy to AT-III or one of its ingredients&#xD;
&#xD;
          -  CPT Class B or C cirrhosis&#xD;
&#xD;
          -  Coagulopathy as indicated by International Normalized Ratio (INR) &gt;= 2.2 or an&#xD;
             inherited coagulation disorder&#xD;
&#xD;
          -  Active hepatitis C infection expecting to initiate HCV therapy within the next two&#xD;
             years&#xD;
&#xD;
          -  Established PVT or cavernoma&#xD;
&#xD;
          -  Transvenous portosystemic shunt (TIPS) placement&#xD;
&#xD;
          -  Previous liver transplantation&#xD;
&#xD;
          -  Increased risk of bleeding:&#xD;
&#xD;
               -  Active pathological bleeding including subjects with actively bleeding esophageal&#xD;
                  varices&#xD;
&#xD;
               -  History of intracranial bleeding&#xD;
&#xD;
               -  Unexplained gastrointestinal bleeding&#xD;
&#xD;
               -  Subjects with large esophageal varices, or varices with endoscopic stigmata of&#xD;
                  bleeding (e.g., red wale sign)&#xD;
&#xD;
               -  Subjects with gastric or intestinal varices&#xD;
&#xD;
               -  Subjects who are taking medicines that increase the risk of thrombosis (e.g.&#xD;
                  tamoxifen)&#xD;
&#xD;
               -  Subjects with any clinically significant bleeding within the last one month&#xD;
&#xD;
               -  Need for therapeutic anticoagulation for another indication&#xD;
&#xD;
               -  Concurrent use of antiplatelet medications excluding aspirin 81 mg once daily as&#xD;
                  aspirin at this dosage does not increase bleeding when given concomitantly with&#xD;
                  AT-III&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Recent major surgery within six weeks&#xD;
&#xD;
          -  Inability or unwilling to give informed consent&#xD;
&#xD;
          -  Hepatocellular carcinoma [diagnosed by cross-sectional imaging, e.g., computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI)] or another active malignancy&#xD;
&#xD;
          -  Predicted lifespan less than two years&#xD;
&#xD;
          -  Severe concurrent disease threatening successful completion of the trial in the&#xD;
             opinion of the study principle investigator&#xD;
&#xD;
          -  Ongoing substance abuse as judged by the study principal investigator and confirmed by&#xD;
             an eight-panel urine drug test at screening&#xD;
&#xD;
          -  Significant alcohol consumption (20g/day for women and 30g/day for men)&#xD;
&#xD;
          -  Human Immunodeficiency Virus infection&#xD;
&#xD;
          -  Worsening liver function based on the two initial laboratory values used to establish&#xD;
             baseline laboratory measurements (section 7.2.2 Monitoring and Intervention Plan for&#xD;
             Drug-induced Liver Injury)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan G Stine, MD</last_name>
    <phone>717531-1017</phone>
    <email>jstine@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gloriany Rivas, BA</last_name>
    <phone>7175310003</phone>
    <phone_ext>320223</phone_ext>
    <email>grivas@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloriany Rivas</last_name>
      <phone>717-531-1017</phone>
      <email>grivas@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Stine</investigator_full_name>
    <investigator_title>Assistant Professor Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

